Lexatumumab-HGS-ETR-2-DataSheet-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemELexatumumabCat.No.:HY-P99299CASNo.:845816-02-6Synonyms:HGS-ETR2;ETR2-ST01;Anti-HumanERBB3RecombinantAntibody作?靶點(diǎn):Apoptosis作?通路:Apoptosis儲(chǔ)存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Lexatumumab(HGS-ETR2)?種?激動(dòng)TRAIL受體2(TRAIL-R2,DR5,APO-2)IgG4κ型單克隆抗體。Lexatumumab在惡性間?瘤中誘導(dǎo)細(xì)胞凋亡(apoptosis)。Lexatumumab可?于惡性胸膜間?瘤(MPM)研究。IC50&TargetTRAIL-R2[1]體外研究ThecombinationofCisplatin(HY-17394)withLexatumumabsynergisticallyinhibitsthecellgrowthandenhancedapoptoticdeath[1].Lexatumumab(0-10μg/ml,72h)inducesvariousdegreesofcelldeathinthedifferentmelanomacelllines[2].CellViabilityAssay[2]CellLine:MelanomacelllinesConcentration:0.01,0.1,1.0and10.0μg/mlIncubationTime:72hResult:Inducedvariousdegreesofcelldeathinthedifferentcelllines.體內(nèi)研究Lexatumumab(10mg/kg,i.v.,twiceaweek)increasesantitumoreffectinvivowhencombinedwithDacarbazine(HY-B0078)[2].1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEAnimalModel:FEMX-1xenograftsmice[2]Dosage:10mg/kg,10mg/kg+Dacarbazine(62.5mg/kgonceaweek,i.p.injection)Administration:i.v.,twiceaweekResult:IncreasedantitumoreffectinvivowhencombinedwithDacarbazine(HY-B0078).Inducedcleavageoflivinintoitstruncated,proapoptoticform,acompoundpreviouslyshowntoaccelerateapoptosis.REFERENCES[1].BelyanskayaLL,etal.HumanagonisticTRAILreceptorantibodiesMapatumumabandLexatumumabinduceapoptosisinmalignantmesotheliomaandactsynergisticallywithcisplatin.MolCancer.2007Oct22;6:66.[2].Enges?terB,etal.DacarbazineandtheagonisticTRAILreceptor-2antibodylexatumumabinducesynergisticanticancereffectsinmelanoma.PLoSOne.2012;7(9):e45492.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820